[go: up one dir, main page]

ATE448226T1 - Aza heterocyclische derivate und ihre therapeutische verwendung - Google Patents

Aza heterocyclische derivate und ihre therapeutische verwendung

Info

Publication number
ATE448226T1
ATE448226T1 AT01973678T AT01973678T ATE448226T1 AT E448226 T1 ATE448226 T1 AT E448226T1 AT 01973678 T AT01973678 T AT 01973678T AT 01973678 T AT01973678 T AT 01973678T AT E448226 T1 ATE448226 T1 AT E448226T1
Authority
AT
Austria
Prior art keywords
sup
therapeutic use
heterocyclic derivatives
pharmaceutically acceptable
aza heterocyclic
Prior art date
Application number
AT01973678T
Other languages
English (en)
Inventor
Paul Renhowe
Tim Machajewski
Cynthia Shafer
Mary-Ellen Wernette-Hammond
Sabina Pecci
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE448226T1 publication Critical patent/ATE448226T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01973678T 2000-09-01 2001-08-30 Aza heterocyclische derivate und ihre therapeutische verwendung ATE448226T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23182900P 2000-09-01 2000-09-01
PCT/US2001/041942 WO2002018383A2 (en) 2000-09-01 2001-08-30 Aza heterocyclic derivatives and their therapeutic use

Publications (1)

Publication Number Publication Date
ATE448226T1 true ATE448226T1 (de) 2009-11-15

Family

ID=22870779

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01973678T ATE448226T1 (de) 2000-09-01 2001-08-30 Aza heterocyclische derivate und ihre therapeutische verwendung

Country Status (9)

Country Link
US (4) US6756383B2 (de)
EP (1) EP1313734B1 (de)
JP (2) JP4341949B2 (de)
AT (1) ATE448226T1 (de)
AU (1) AU2001293233A1 (de)
DE (1) DE60140456D1 (de)
ES (1) ES2334641T3 (de)
PT (1) PT1313734E (de)
WO (1) WO2002018383A2 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756383B2 (en) 2000-09-01 2004-06-29 Chiron Corporation Heterocyclic derivatives of quinolinone benimidazoles
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
DE60115069T2 (de) * 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
US7642278B2 (en) * 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
EP1401831A1 (de) * 2001-07-03 2004-03-31 Chiron Corporation Indazol-benzimidazol-derivate als tyrosin- und serin/threonin-kinase-inhibitoren
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
KR20050037585A (ko) * 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
WO2004030620A2 (en) * 2002-09-30 2004-04-15 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
WO2004043389A2 (en) * 2002-11-13 2004-05-27 Chiron Corporation Methods of treating cancer and related methods
WO2004063151A2 (en) * 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
JP2006516626A (ja) * 2003-01-28 2006-07-06 スミスクライン ビーチャム コーポレーション 化学的化合物
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
MXPA06004194A (es) * 2003-11-07 2006-06-28 Chiron Corp Inhibicion de fgfr3 y tratamiento de mieloma multiple.
FR2862969A1 (fr) 2003-11-28 2005-06-03 Oreal Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
BRPI0507891A (pt) * 2004-02-20 2007-07-24 Chiron Corp modulação dos processos inflamatório e metastático
BRPI0607285A2 (pt) 2005-01-27 2009-08-25 Novartis Vaccines & Diagnostic tratamento de tumores com metástases
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
HUE030881T2 (en) 2005-02-18 2017-06-28 Glaxosmithkline Biologicals Sa Meningitis / sepsis-associated escherichia coli proteins and nucleic acids
PT1885187E (pt) * 2005-05-13 2013-12-16 Novartis Ag Métodos para o tratamento de cancro resistente a fármacos
KR101324863B1 (ko) 2005-05-17 2013-11-01 노파르티스 아게 헤테로고리 화합물의 합성 방법
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
EP2270000B1 (de) * 2005-05-23 2015-07-29 Novartis AG Kristalline und andere Formen von 4-Amino-5-Fluor-3-[6-(Methylpiperazin-1-yl)-1H-Benzimidazol-2-yl]-1H-Chinolin-2-on-Milchsäuresalz
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
CA2615626A1 (en) 2005-07-18 2007-01-25 Novartis Ag Small animal model for hcv replication
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514841A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 粒子状アジュバントと免疫増強物質との組合せを含むインフルエンザワクチン
EP2377552A3 (de) 2005-11-04 2013-05-15 Novartis Vaccines and Diagnostics S.r.l. Influenzaimpfstoffe mit reduzierter Anzahl von Emulsionshilfsmitteln
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
KR20080074143A (ko) 2005-11-29 2008-08-12 노파르티스 아게 퀴놀리논 제제
RU2008127252A (ru) 2005-12-08 2010-01-20 Новартис АГ (CH) Эффекты ингибиторов fgfr3 на транскрипцию генов
DK1976559T6 (da) 2006-01-27 2020-04-06 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
EP2054431B1 (de) 2006-06-09 2011-08-31 Novartis AG Bakterielle adhäsine konformere
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
CA2671629C (en) 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
GB0800855D0 (en) * 2008-01-17 2008-02-27 Syngenta Ltd Herbicidal compounds
EP3459563A1 (de) 2008-03-18 2019-03-27 Seqirus UK Limited Verbesserungen bei der herstellung von influenzavirusimpfstoffantigenen
CA2754618A1 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
MX363222B (es) 2009-04-14 2019-03-15 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
EP2424565A1 (de) 2009-04-27 2012-03-07 Novartis AG Adjuvantierte impfstoffe zum schutz vor grippe
AU2010269961A1 (en) 2009-07-07 2012-02-02 Novartis Ag Conserved Escherichia coli immunogens
EP3988115A3 (de) 2009-07-15 2022-08-17 GlaxoSmithKline Biologicals S.A. Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
EP2464658B1 (de) 2009-07-16 2014-10-01 Novartis AG Detoxifizierte escherichia coli immunogene
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
WO2011051212A1 (de) * 2009-10-28 2011-05-05 Basf Se Verwendung heteroaromatischer verbindungen als herbizide
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
ES2707778T3 (es) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US10342862B2 (en) 2011-01-26 2019-07-09 Glaxosmithkline Biologicals, Sa RSV immunization regimen
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
US9181214B2 (en) 2011-06-09 2015-11-10 Rhizen Pharmaceuticals Sa Bicyclic compounds as modulators of GPR-119
EP2729178A1 (de) 2011-07-08 2014-05-14 Novartis AG Tyrosinverbindungsverfahren
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
EP2903650B1 (de) 2012-10-02 2018-04-04 GlaxoSmithKline Biologicals SA Nichtlineare saccharidkonjugate
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
EP2977374A1 (de) * 2014-07-21 2016-01-27 Université de Strasbourg Moleküle mit zwei Emissionseigenschaften
SI3322711T1 (sl) * 2015-06-25 2021-08-31 University Health Network Zaviralci HPK1 in postopek njihove uporabe
CN107935858B (zh) * 2016-10-12 2020-09-08 利尔化学股份有限公司 5-氟-2-硝基苯酚的制备方法
MX2020005342A (es) * 2017-11-24 2020-10-14 Janssen Pharmaceutica Nv Compuestos de pirazolopiridinona.
ES2926518T3 (es) * 2017-11-24 2022-10-26 Janssen Pharmaceutica Nv Compuestos de pirazolopiridinona
TW202203917A (zh) * 2020-04-13 2022-02-01 加拿大健康網路大學 治療細胞激素釋放症候群之方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE290153C (de)
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
DE3634066A1 (de) 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
DE3739366A1 (de) 1987-04-10 1988-10-27 Boehringer Mannheim Gmbh Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9107742D0 (en) 1991-04-11 1991-05-29 Rhone Poulenc Agriculture New compositions of matter
GB9108369D0 (en) 1991-04-18 1991-06-05 Rhone Poulenc Agriculture Compositions of matter
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
ES2108120T3 (es) * 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE239506T1 (de) 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
WO1995018801A1 (en) 1994-01-08 1995-07-13 Rhone-Poulenc Agriculture Ltd. Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
AU3102697A (en) 1996-06-19 1998-01-07 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
CN1226245A (zh) 1996-06-20 1999-08-18 德克萨斯州大学系统董事会 具有药理活性的化合物,其制备方法及其用途
US6809097B1 (en) 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
WO2001052904A2 (en) 2000-01-19 2001-07-26 Gill Parkash S Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
WO2000012089A1 (en) * 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
WO1999050263A1 (en) * 1998-03-31 1999-10-07 Warner-Lambert Company Quinolones as serine protease inhibitors
AU3850299A (en) 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
AU4956699A (en) 1998-06-19 2000-01-05 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
WO2000020400A1 (en) 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
KR100373203B1 (ko) 1999-03-31 2003-02-25 주식회사 엘지화학 새로운 큐마린계 착물 및 이를 이용한 유기 발광 소자
JP4649046B2 (ja) 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
CA2387351C (en) 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
WO2001028993A2 (en) * 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
WO2001062252A1 (en) 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6756383B2 (en) 2000-09-01 2004-06-29 Chiron Corporation Heterocyclic derivatives of quinolinone benimidazoles
DE60115069T2 (de) * 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
EP1328519B1 (de) 2000-10-17 2005-09-07 Merck & Co., Inc. Oral aktive salze mit tyrosinkinaseaktivität
EP1401831A1 (de) 2001-07-03 2004-03-31 Chiron Corporation Indazol-benzimidazol-derivate als tyrosin- und serin/threonin-kinase-inhibitoren
KR20050037585A (ko) 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
WO2004030620A2 (en) 2002-09-30 2004-04-15 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
WO2004043389A2 (en) 2002-11-13 2004-05-27 Chiron Corporation Methods of treating cancer and related methods
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
MXPA06004194A (es) 2003-11-07 2006-06-28 Chiron Corp Inhibicion de fgfr3 y tratamiento de mieloma multiple.
WO2005054183A2 (en) 2003-12-01 2005-06-16 The Scripps Research Institute Quinolinone based protein kinase inhibitors
BRPI0607285A2 (pt) 2005-01-27 2009-08-25 Novartis Vaccines & Diagnostic tratamento de tumores com metástases

Also Published As

Publication number Publication date
WO2002018383A3 (en) 2002-08-29
US6759417B2 (en) 2004-07-06
EP1313734B1 (de) 2009-11-11
US7368459B2 (en) 2008-05-06
US20020103230A1 (en) 2002-08-01
JP4341949B2 (ja) 2009-10-14
AU2001293233A1 (en) 2002-03-13
JP2004507543A (ja) 2004-03-11
US20050137188A1 (en) 2005-06-23
US20040002518A1 (en) 2004-01-01
JP2007217427A (ja) 2007-08-30
US7138409B2 (en) 2006-11-21
WO2002018383A2 (en) 2002-03-07
PT1313734E (pt) 2010-02-09
ES2334641T3 (es) 2010-03-15
EP1313734A2 (de) 2003-05-28
US6756383B2 (en) 2004-06-29
DE60140456D1 (de) 2009-12-24
US20070032528A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
ATE448226T1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
ATE180468T1 (de) Anthranilsäure derivate
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DE69835430D1 (de) Sulfonamidderivate, ihre herstellung und verwendung
EA200400893A1 (ru) N-арил-2-оксазолидинон-5-карбоксамиды, их производные и их применение в качестве антибактериальных средств
DE69933573D1 (de) Chinazolinderivate als medikamente
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
KR960701878A (ko) 수용성 캄프토테신 유도체, 이의 제조 방법 및 항종양제로서의 이의 용도(Water-soluble camptothecin derivatives, process for their preparation and their use as antitumor agents)
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
DE69425162D1 (de) 4,5-diaryloxazol-derivate
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
DE69027235D1 (de) Xanthinderivate
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
EA199800794A1 (ru) Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения
EP1167366A4 (de) Aminderivate
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
PT992509E (pt) Novos derivados macrolidos
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
YU30603A (sh) Derivati premošćenog piperazina
DE69330601D1 (de) Serotoninergische ergolin derivate
DE69813886D1 (de) Naphthalin derivate
ATE170851T1 (de) Guanidinothiazolederivate und ihre anwendung als h2-rezeptor-antagonisten
EP2266566A3 (de) Nicotinamid Derivate und ihrer Verwendung als Therapeutika
ATE258934T1 (de) Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1313734

Country of ref document: EP

REN Ceased due to non-payment of the annual fee